Past Event
日期
September 10-12, 2023
Location
Bellevue, WA
Booth #3
2023 ACCP Annual Meeting
Sunday, September 10th, 3:10 PM – 3:30 PM (PT)
Antibody-drug Conjugates in the Clinic: Key Considerations & the Role of Modeling in Expediting Development
Julie Bullock, PharmD, Senior Vice President, Global Head of Clinical Pharmacology & Translational Medicine & Ian Templeton, PhD, Senior Director of PBPK Consulting
Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a cytotoxic anti-cancer drug directly to the tumor with reduced off-target damage. ADCs combine the targeting capability of monoclonal antibodies with the cancer-killing capability of the payload (linker + cytotoxic drug). In this presentation, we will give an overview on the functionality of the ADC module within the Simcyp™ Simulator and how it can be applied to ADC drug development. In addition, we will reflect on the key drug development considerations from the lens of clinical pharmacology and drug metabolism/pharmacokinetics (DMPK).
Monday, September 11 | 11:45 AM – 1:15 PM
1 – Roger Jelliffe Individualized Therapy Award: A Personal Account of Paving the Road to Personalized Medicine
Karen Rowland-Yeo, Ph.D.
|Senior Vice President
Monday, September 11 | 1:30 PM – 5:00 PM | Grand Ballroom E-H
Symposium 7: Are Mechanistic Models Necessary or Nice-to-Have in the Development of Multispecific Antibodies?: 1 – Mechanistic Models for Multispecific Antibodies: An Introduction
Piet van der Graaf, PhD, PharmD
|Senior Vice President
Monday, September 11 | 1:30 PM – 5:00 PM | Grand Ballroom E-H
Symposium 7: Are Mechanistic Models Necessary or Nice-to-Have in the Development of Multispecific Antibodies?: 8 – The Role of Model-informed Drug Development & QSP in Project Optimus
Julie Bullock, PharmD
|Senior Vice President, Global Head of Clinical Pharmacology & Translational Medicine
海报
FDA Trends for Accelerated Drug Approvals in Oncology Indications
Jennifer Schneider, Ph.D.
|Director Clinical Pharmacology
海报
Adoption of PROs in Early Clinical Trials for Oncology Drugs: Challenges and Opportunities
Alice Toms, Ph.D.
|Sr. Biostatistician
海报
PBPK Application in Drug Discovery and Development
Kuan-Fu (Freddy) Chen, Ph.D.
|Principal PBPK Consultant
